Innate Pharma (Innate Pharma) Common Stock : $4.41 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Common Stock?

Innate Pharma's quarterly common stock increased from Dec. 2022 ($4.25 Mil) to Jun. 2023 ($4.36 Mil) and increased from Jun. 2023 ($4.36 Mil) to Dec. 2023 ($4.41 Mil).

Innate Pharma's annual common stock declined from Dec. 2021 ($4.50 Mil) to Dec. 2022 ($4.25 Mil) but then increased from Dec. 2022 ($4.25 Mil) to Dec. 2023 ($4.41 Mil).

Innate Pharma Common Stock Historical Data

The historical data trend for Innate Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Common Stock Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

4.38

4.81

4.50

4.25

4.41

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial															4.50	4.22	4.25	4.36	4.41

Innate Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.